Two-stage liver transplantation, involving a total hepatectomy with a temporary portocaval shunt followed by liver transplantation, requires intensive perioperative care, especially during the prolonged anhepatic period. The pathophysiology and management of this prolonged anhepatic state is not fully elucidated and the proper management during this period is a great challenge to clinicians in the intensive care unit and anesthesiologists. We report a case and management of a total hepatectomy with a temporary portocaval shunt followed by living-donor liver transplantation in a patient with a surgically complicated liver failure after a hepatic tumor resection. (Korean J Anesthesiol 2010; 59: 348-352)

Key Words: Anhepatic, Hepatectomy, Liver failure, Liver transplantation, Portocaval shunt, Two-stage procedure.

Case Report

A 42-year-old woman (weight: 48.8 kg, height: 159 cm), who underwent an extensive tumor resection for Klatskin tumor, Bismuth type IV, developed acute hepatic failure in the time of a total hepatectomy and proper care of the anhepatic state may affect the outcome of the patient after this two-stage procedure [2]. We report a case and perioperative care of a total hepatectomy with a temporary portocaval shunt followed by living-donor LT in a patient with surgically complicated liver failure after a hepatic tumor resection.
the immediate postoperative period and was listed for an emergency LT.

A preoperative laboratory and radiology evaluation before the tumor resection were within the normal limits except for an elevated liver function profile (aspartate aminotransferase 170 U/L, alanine aminotransferase 100 U/L) due to the underlying Klatskin tumor. The bleeding diatheses at the intensive care unit (ICU) were as follows: hemoglobin and platelet count decreased from 10.4 g/dl and 103 x 10^9/μl to 4.8 g/dl and 60 x 10^9/μl, respectively, within the first hour at the ICU. Prothrombin time (PT) expressed in the international normal range (INR), activated partial thrombin time (aPTT), fibrinogen, fibrin degradation product, D-dimer, antithrombin III activity, plasminogen activity, protein C activity were 2.03 (normal [nl], 0.9–1.1), 104.5 seconds (nl, 29–42 seconds), 97 mg/dl (nl, 180–380 mg/dl), >5 µg/ml (nl, <5 µg/ml), 3.23 µg/ml (nl, 0–0.5 µg/ml), 41% (nl, 83–123%), 30% (nl, 75–112%), 43% (nl, 80–161%), respectively. Metabolic acidosis of pH <7.15 with a progressively deteriorating base deficit >15 mmol/L and exacerbating hypocalcemia <0.8 mol/l and hyperglycemia >200 mg/dl were observed throughout the ICU stay. Continuous infusions of calcium gluconate at 1 mg/kg/hr and 5% albumin and dextrose solution were provided as needed. There was no neurological deficits following the abnormal changes in sodium level or signs of hepatic encephalopathy, even though comprehensive neurological examinations were not feasible due to the patient’s sedated and intubated condition. The serum glucose level was maintained between 100 and 200 mg/dl. A warm blanket was applied to maintain the normal body temperature. An inotropic support with a continuous infusion of 5 µg/kg/min dopamine maintained the systolic blood pressure between 80 and 100 mmHg and diastolic blood pressure between 60 and 80 mmHg. At the discretion of the ICU specialist, 12 units of packed red blood cells, 10 units of fresh frozen plasma, 16 units of platelet concentrates and 14 units of cryoprecipitate were given over an 11-hour period at the ICU before the liver transplant. An elevated creatinine level of 1.58 mg/dl and urine out of <10 ml/hr were observed, but continuous renal replacement therapy (CRRT) was not applied. The coagulation profile during the anhepatic period showed a prolongation of PT (INR) around 2, aPTT around 100 s and fibrinogen <100 mg/dl. Cytokine or other toxin related laboratory analyses were not performed in this patient. No artificial liver support, such as molecular adsorbent recirculating system (MARS), was applied in this patient because she was not considered a suitable candidate.

The patient was anhepatic for 15 hours before reperfusion of the liver in the living donor liver transplantation. Anesthesia was induced and maintained with desflurane at an oxygen fraction of 0.5 under routine monitoring with electrocardiography, SpO2, radial and femoral arterial pressure, pulmonary arterial pressure and cardiac output. Continuous vasoactive support with 5 µg/kg/min dopamine and 0.1–0.2 µg/kg/min norepinephrine were maintained. The hemodynamic profile was stable throughout the operation before and after reperfusion of the transplanted liver. During the seven hour and 40 minute LT operation, 7,500
ml crystalloid, 500 ml colloid, 650 ml albumin, eight units of packed red blood cell, four units of fresh frozen plasma, nine units of cryoprecipitate and one unit of platelet apheresis were administered.

Postoperative care at the ICU involved cardiovascular and respiratory support with a CCRT. On the ninth day after LT, the patient became alert and on the 16th day she was extubated for one week until reintubated due to pulmonary effusion related respiratory failure. The acute renal insufficiency with urine output of <5 ml/hr and creatinine level between 1.5 and 2.0 mg/dl persisted despite the best efforts to improve the renal function. The patient also suffered peritonitis from bowel anastomosis leakage and underwent two additional operations for anastomosis site repair. The sustained septic conditions throughout the ICU stay aggravated and progressed to multiorgan failure. The patient died on postoperative day 65.

Discussion

A total hepatectomy with a portocaval shunt was performed as a bridging procedure to a LT because the patient developed acute liver failure, which manifested as uncontrollable massive bleeding and so-called “toxic liver syndrome” immediately after a surgical resection of a Klatskin tumor.

Toxic liver syndrome is one of the major indications for this procedure and it is known to occur after acute or fulminant hepatic necrosis that is often complicated by multiorgan failure, such as cardiovascular shock, renal failure, pulmonary insufficiency and cerebral dysfunction. The multiorgan involvement is caused by many factors including toxic metabolites released from the necrotized liver and endogenous vasoactive materials. The mortality of this condition is rated nearly 100%. Therefore, the elimination of the necrotized liver was
Anhepatic patients develop hypoglycemia because the liver is the main source of glycogen storage, therefore needs to be replaced with an intravenous glucose infusion. Hypothermia needs to be managed with a warm blanket and the body temperature needs to be maintained. Oliguria and renal failure often develop rapidly within 24 hours of an anhepatic state, and early renal dysfunction might indicate a poor prognosis. Renal insufficiency is reported to be related to the prevalence of postoperative sepsis. Supports to provide renal perfusion by diuretics, mannitol or renal dose dopamine infusion may be considered [8]. Some clinicians run CCRT and some even prefer to apply it prophylactically. Our patient also became rapidly oliguric but CCRT was not applied. Ionic hypocalcemia is severe in prolonged anhepatic periods because citrate from the blood product accumulates without being metabolized due to the absence of liver [11]. Our patient also showed persistent hypocalcemia despite the continuous infusion of calcium supplements throughout the anhepatic period (Fig. 1). Vigorous calcium replacement is recommended because severe hypocalcemia can result in negative cardiac output and hemodynamic compromise. Coagulation defects in anhepatic patients are not as severe as indicated by the conventional laboratory results, and may be treated with fresh frozen plasma and fibrinogen [8]. Anhepatic patients also need to be cautioned regarding sepsis and multiorgan failure as these are reportedly the main cause of mortality. Although our patient also suffered and died of sepsis and multiorgan failure, her septic condition was confounded by peritonitis that was complicated from bowel anastomosis leakage. It is unclear if the complicated peritonitis persisted because of the patient’s immune downfall. The transplanted liver was considered to be in good function as the patient recovered consciousness on the ninth postoperative day without any signs of graft rejection. Therefore, the patient would have survived the liver transplant and lived had it not been for the complicated bowel anastomosis leakage.

The safety margin of time for a prolonged anhepatic state is also not known. The maximum duration of 41 hours, 60 hours and a range of 6.58 to 72.5 hours were reported by Ringe et al. [2], Bentdal et al. [4], and Oldhafer et al. [12] respectively. In this patient, the anhepatic time was 15 hours. The survival rate varied from study to study, but was >60% overall [10]. The permissible anhepatic time for a better prognosis or its correlation with a deterioration of the patient’s condition are difficult to define because the survival varies according to the clinical status of the patient at the time of the total hepatectomy and the effectiveness of supportive care before and after the two-stage procedure [2]. The best prognosis appears to depend mostly on the patient’s factors and prompt availability of a liver graft. In this regard, a living donor liver transplant may be advocated even in an emergent situation because a cadaveric donor may not be available in a timely manner.

Along with this two-stage procedure, there have been other efforts, such as the use of liver support devices, to sustain the acute or fulminant liver failure patients until a liver graft is ready [13,14]. Bioartificial liver support using charcoal columns and extracorporeal devices filled with the liver tissue has been reported [13], and more recently the MARS has been introduced as a nonbiological liver support device [14,15]. The application of these devices is a relatively common clinical practice because they remove toxic materials from the patients’ plasma, thus providing the patients with more time to wait for a liver graft by improving the hemodynamic profiles and alleviating the increased intracranial pressure. The MARS was not applied in this patient after the extensive hepatic tumor resection because she suffered from acute liver failure not confounded by chronic liver diseases and was not considered a suitable candidate. Her medical condition did not progress to develop hepatic encephalopathy or other extensive toxic status that would necessitate the application of the MARS during the anhepatic period.

Different anesthetic demands and management schemes are needed for the LT in a two stage procedure compared to LT in general. In the two stage procedure, LT is not prone to develop massive bleeding as is the case in a routine LT procedure because hepatectomy and portocaval shunt have already been performed. In addition, the hemodynamic instability originating from clamping of the portal vein does not occur.
not occur during LT in the two stage procedure. Patient care at the ICU during the anhepatic period and anesthetic patient management at the beginning of the LT surgical procedure may share a uniform rationale regarding the ongoing prolonged status of the anhepatic stage even from the start of the operation compared to a routine LT. An evaluation of the calcium level and its replacement are needed more frequently at the ICU because hypocalcemia is particularly severe in these transplant recipients.

In conclusion, a total hepatectomy and temporary portocaval shunt may be performed successfully as a bridging procedure to liver transplantation if backed up with an adequate management during the anhepatic period.

References

1. Ringe B, Pichlmayr R, Lübbe N, Bornscheuer A, Kuse E. Total hepatectomy as temporary approach to acute hepatic or primary graft failure. Transplant Proc 1988; 20(1 Suppl 1): 552-7.
2. Ringe B, Lübbe N, Kuse E, Frei U, Pichlmayr R. Total hepatectomy and liver transplantation as a two-stage procedure. Ann Surg 1993; 218: 3-9.
3. Henderson A, Webb I, Lynch S, Kerlin P, Strong R. Total hepatectomy and liver transplantation as a two-stage procedure in fulminating hepatic failure. Med J Aust 1994; 161: 318-9.
4. Bentdal O, Brekke IB, Olausson M, Foss A, Husberg B, Ostensen A, et al. Living related liver retransplantation in a 6-month-old child after 60 hours of anhepatic phase following hepatectomy of thrombosed primary liver graft. Transplant Proc 2001; 33: 2497-8.
5. Ferraz-Neto BH, Moraes-Junior JM, Hidalgo R, Zurstrassen MP, Lima IK, Novais HS, et al. Total hepatectomy and liver transplantation as a two-stage procedure for toxic liver: case reports. Transplant Proc 2008; 40: 814-6.
6. Detry O, De Roover A, Delwaide J, Hans MF, Canivet JL, Meurisse M, et al. Prolonged anhepatic state after early liver graft removal. Hepatogastroenterology 2007; 54: 2109-12.
7. Trotter JF. Practical management of acute liver failure in the Intensive Care Unit. Curr Opin Crit Care 2009; 15: 163-7.
8. Ozier Y, Klinck JR. Anesthetic management of hepatic transplantation. Curr Opin Anaesthesiol 2008; 21: 391-400.
9. Vaquero J, Fontana RJ, Larson AM, Bass NM, Davern TJ, Shapko AO, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005; 11: 1581-9.
10. Bustamante M, Castroagudín JF, González-Quintela A, Martínez J, Segade FR, Fernández A, et al. Intensive care during prolonged anhepatic state after total hepatectomy and porto-caval shunt (two-stage procedure) in surgical complications of liver transplantation. Hepatogastroenterology 2000; 47: 1343-6.
11. Martin TJ, Kang Y, Robertson KM, Virji MA, Marquez JM. Ionization and hemodynamic effects of calcium chloride and calcium gluconate in the absence of hepatic function. Anesthesiology 1990; 73: 62-5.
12. Oldhafer KJ, Bornscheuer A, Frühauf NR, Frerker MK, Schlitt HJ, Ringe B, et al. Rescue hepatectomy for initial graft non-function after liver transplantation. Transplantation 1999; 67: 1024-8.
13. Hui T, Rozga J, Demetriou AA. Bioartificial liver support. J Hepatobiliary Pancreat Surg 2001; 8: 1-15.
14. Pugliese F, Ruberto F, Perrella SM, Cappannoli A, Bruno K, Martelli S, et al. Modifications of intracranial pressure after molecular adsorbent recirculating system treatment in patients with acute liver failure: case reports. Transplant Proc 2007; 39: 2042-4.
15. Pugliese F, Novelli G, Poli L, Levi Sandri GB, Di Folco G, Ferretti S, et al. Hemodynamic improvement as an additional parameter to evaluate the safety and tolerability of the molecular adsorbent recirculating system in liver failure patients. Transplant Proc 2008; 40: 1925-8.